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Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins
engineered from human components
Abstract
New World monkeys of the genus Aotus synthesize a fusion protein (AoT5Cyp) containing tripartite
motif-containing 5 (TRIM5) and cyclophilin A (CypA) that potently blocks HIV-1 infection. We
attempted to generate a human HIV-1 inhibitor modeled after AoT5Cyp, by fusing human CypA to
human TRIM5 (hT5Cyp). Of 13 constructs, 3 showed substantial HIV-1-inhibitory activity when
expressed in human cell lines. This activity required capsid binding by CypA and correlated with CypA
linkage to the TRIM5a capsid-specificity determinant and the ability to form cytoplasmic bodies.
CXCR4- and CCR5-tropic HIV-1 clones and primary isolates were inhibited from infecting multiple
human macrophage and T cell lines and primary cells by hT5Cyp, as were HIV-2ROD, SIVAGMtan,
FIVPET, and a circulating HIV-1 isolate previously reported to be AoT5Cyp resistant. The anti-HIV-1
activity of hT5Cyp was surprisingly more effective than that of the well-characterized rhesus
TRIM5alpha, especially in T cells. hT5Cyp also blocked HIV-1 infection of primary CD4+ T cells and
macrophages and conferred a survival advantage to these cells without disrupting their function.
Extensive attempts to elicit HIV-1 resistance to hT5Cyp were unsuccessful. Finally, Rag2-/-gammac-/-
mice were engrafted with human CD4+ T cells that had been transduced by optimized lentiviral vectors
bearing hT5Cyp. Upon challenge with HIV-1, these mice showed decreased viremia and productive
infection in lymphoid organs and preserved numbers of human CD4+ T cells. We conclude that hT5Cyp
is an extraordinarily robust inhibitor of HIV-1 replication and a promising anti-HIV-1 gene therapy
candidate.
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Identification of human T5Cyp proteins 
that potently restrict HIV-1. (A) The 
sequence of hTRIM5α protein. Lower-
case letters indicate the register of the 
predicted coiled coils. Boxed areas 
indicate PRYSPRY residues. Vertical 
lines indicate the site of fusion of CypA 
to TRIM5. Numbers indicate the TRIM5 
amino acid to which CypA is fused, and 
are color coded for restriction phenotype 
(red, potently restrictive; orange, variably 
restrictive; green, permissive). (B) Jurkat 
T cells and THP-1 monocytes were trans-
duced with vectors encoding puromycin 
resistance and either AoT5Cyp or hT5Cyp 
(hT5-S222-Cyp) fusion proteins. Pools of 
puromycin-resistant cells were infected 
with increasing amounts of a single-cycle 
HIV-1 vector encoding GFP (measured as 
RT units). The percentage of GFP+ cells 
was determined 48 hours later.
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HIV-1 restriction activity correlates with CypA fusion to the TRIM5α specificity determinant and the ability to form cytoplasmic bodies. (A) Expres-
sion of hT5Cyp fusion proteins. FLAG-hT5Cyp fusion proteins synthesized in 293T cells were immunoprecipitated with anti-FLAG antibodies and 
immunoblotted with anti-CypA antibodies. (B) HIV-1 CA binding activity of hT5Cyp fusion proteins. FLAG-hT5Cyp and GST-CA fusion proteins 
were co-expressed in 293T cells, pulled out on glutathione-sepharose beads in the presence or absence of 20 μM CsA, and immunoblotted with 
anti-CypA and anti–p24-CA antibodies. (C) Model of the PRYSPRY domain of hTRIM5α based on crystal structures of PRYSPRY, GUSTAVUS, 
and TRIM21. Two ribbon representations showing the position of hCypA fusions (spheres) to the hTRIM5α PRYSPRY domain. The grey trans-
parent ribbon indicates regions of the model that would be replaced by CypA in hT5-S331-Cyp. (D) Restrictive T5Cyp fusion proteins formed 
discrete puncta in the cytoplasm. Indirect immunofluorescence images of CRFK cells stably expressing the indicated T5Cyp fusions. Fixed 
samples were stained with anti-TRIM5 antibody (green) and anti-tubulin antibody (red), followed by counterstain with DAPI (blue) to visualize the 
nuclear DNA. For each color, an individual stack of twenty 0.35-μm optical sections was acquired and subjected to maximum intensity projection 
along the optical axis. Images represent 3-color overlays. Scale bar: 5 μm. All panels are color coded for restriction phenotype (red, restrictive; 
orange, variably restrictive; green, permissive).
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TRIM5 and CypA components each 
make essential contributions to T5Cyp 
restriction activity. (A–C) Disruption of 
the CA-CypA interaction by the G89V 
mutation in HIV-1 CA (A), the H126Q 
mutation in CypA (B), or the competi-
tive inhibitor CsA at 2.5 μM (C) blocked 
HIV-1 restriction activity in CRFK cells 
stably expressing the indicated TRIM5 
proteins or controls. Cells were chal-
lenged with increasing amounts of 
HIV-1–GFP single-cycle vector bear-
ing the G89V mutation in CA (A) or 
wild-type HIV-1 GFP vector (B and C). 
(D) Introduction of a naturally occur-
ring quadruple mutation flanking the 
CA-CypA binding site in HIV-1 CA 
did not abrogate hT5Cyp-mediated 
restriction of HIV-1. CRFK cells sta-
bly expressing T5Cyp or control were 
infected with increasing amounts of 
an HIV-1 GFP vector containing the 
V86P/H87Q/I91V/M96I mutation in 
CA. (E) Disruption of TRIM5 by As2O3 
blocked HIV-1 restriction activity by 
T5Cyp. CRFK cells stably express-
ing the indicated T5Cyp were infected 
with HIV-1 GFP vector in the pres-
ence of increasing amounts of As2O3. 
In each case, the percentage of GFP+ 
cells was measured by flow cytometry 
48 hours after infection.
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hT5Cyp eliminates the spread of HIV-1 in tissue culture. Jurkat T 




















T5Cyp potently restricts lentiviruses 
that encode CA with CypA-binding 
activity. (A–E) CRFK cells stably 
expressing the indicated TRIM5 pro-
teins were transduced with increas-
ing amounts of single-cycle GFP 
vectors derived from HIV-1NL4-3 (A), 
HIV-2ROD (B), SIVAGMtan (C), FIVPET 
(D), or SIVMAC251 (E). The percent-
age of GFP+ cells was determined 
48 hours later.
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The anti–HIV-1 activity of hT5Cyp 
is superior to that of rhTRIM5α. 
(A and B) CRFK (A) and Jurkat 
T cells (B) were transduced with 
lentiviral vectors encoding the indi-
cated TRIM5 proteins and a puro-
mycin resistance cassette. Pools 
of puromycin-resistant cells were 
infected with increasing amounts 
of a single-cycle HIV-1–GFP vec-
tor. The percentage of GFP+ cells 
was determined 48 hours later. 
(C and D) As in A and B, Jurkat 
T cells were transduced with the 
indicated vectors and challenged 
with HIV-1NL4-3-GFP-IRES-Nef. The 
percentage of infected cells was 
determined by flow cytometry.
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New lentiviral vectors bearing 
hT5Cyp potently block replica-
tion-competent HIV-1 in primary 
cells. (A) Design of conventional 
bicistronic (AIG) and new dual-
promoter (scALPS) lentiviral 
vectors. (B) Forty-eight hours 
after transduction with AIG and 
scALPS vectors, Jurkat T cells 
and primary hCD4+ T cells were 
analyzed by flow cytometry for 
GFP. (C and D) Primary human 
CD4+ T cells transduced with 
scALPS encoding the indicated 
hT5Cyp proteins were sorted 
for GFP and infected with lab 
clone HIV-1NL4-3 (C) or primary 
isolate HIV-1DH12 (D), and RT 
activity in the supernatant was 
measured. Triplicate spreading 
infection for 1 representative 
donor of 4 is shown. (E and F) 
Human macrophages gener-
ated from GM-CSF–treated, 
CD14+ monocytes were trans-
duced with the indicated vec-
tors, sorted for GFP, and chal-
lenged with modified HIV-1NL4-3 
bearing a CCR5-tropic Env (E) 
or primary isolate HIV-1132W 
(F). Infection was monitored as 
described in C and D. Error bars 
in C and E represent SEM. n = 3. 
(G) hT5Cyp-bearing CD4+ T 
cells exhibit a selective advan-
tage after challenge with HIV-1. 
CD4+ T cells were transduced 
with scALPS encoding the indi-
cated T5Cyp proteins. Cultures 
containing 23% GFP+ cells 
were challenged with HIV-1NL4-3 
(15 ng p24/106 cells), and the 
percentage of GFP+ cells was 
monitored (left y axis, open sym-
bols). Supernatant RT activity 
was measured (right y axis, filled 
symbols). Cultures were restim-
ulated using allogeneic PBMCs, 
IL-2, and PHA 26 days following 
infection (arrow).
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Adoptive transfer of hT5Cyp-tranduced hCD4 cells into Rag2–/–γc–/– 
mice. Human peripheral blood CD4+ T cells transduced with lentiviral 
vector scALPS bearing either hT5Cyp or hT5CypH126Q were sorted 
for GFP and injected into 6- to 10-week-old Rag2–/–γc–/– mice. The 
experimental design is shown schematically in A. (B) Flow cytometric 
analysis of the transduced, sorted cells prior to adoptive transfer. Left: 
Nearly all cells were hCD4+. Right: GFP fluorescence in transduced 
cells (open histograms, scALPS) or in untransduced, donor-identi-
cal CD4+ T cells (grey histogram; mock). (C) Six weeks after trans-
plant, single-cell suspensions of thymus were analyzed for human cell 
engraftment and transgene expression. Left: Recipient-derived CD45+ 
mouse cells (mCD45.2) and donor-derived hCD45+ cells. Right: CD4 
and GFP signals for the hCD45+ cells. In B and C, the numbers indi-
cate the percentage of cells within the gates.
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hT5Cyp inhibits HIV-1 in a humanized mouse model. Rag2–/–γc–/– mice (6–10 weeks old) were engrafted with GFP-sorted scALPS-transduced 
CD4+ T cells expressing either hT5Cyp or hT5CypH126Q. (A) Five days after engraftment, mice were challenged with HIV-1NL4-3. The percent-
age of hCD4+ T cells among all nucleated cells in the peripheral blood of individual mice is shown at 2 weeks following infection. The fold differ-
ence for the mean is indicated (horizontal bars, ***P = 0.0002, Mann-Whitney U test). (B–E) Two weeks after engraftment, mice were infected 
with HIV-1NL4-3. (B) Plasma viral load for individual mice was determined 3 weeks after infection. The fold difference in the mean is indicated 
(horizontal bars; **P = 0.005, Mann-Whitney U test). (C and D) Three weeks after infection, single-cell suspensions from thymus were analyzed 
by flow cytometry for p24 and hCD3 cells (C) or hCD45 and hCD4 (D). The numbers indicate the percentage of cells within the gates. (E) Paraf-
fin-embedded sections of thymus are shown, stained with H&E, anti-hCD3, or anti-p24, as indicated. All panels are at ×40 magnification, except 
the 2 right panels, which are ×80 magnification. In C–E, representative results from 3 sets of experiments are shown.
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